A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) Meeting Abstract
| Authors: | Janjigian, Y. Y.; Viglianti, N.; Liu, F.; Mendoza-Naranjo, A.; Croydon, L. |
| Abstract Title: | A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) |
| Meeting Title: | 2021 Gastrointestinal Cancers Symposium (ASCO GI) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 15-17 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-01-20 |
| Language: | English |
| ACCESSION: | WOS:000636712800029 |
| DOI: | 10.1200/JCO.2021.39.3_suppl.TPS261 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS261 -- Source: Wos |
